JPRN-UMIN000016995
Recruiting
未知
Evaluation of antiviral effects of the combination therapy of daclatasvir and asunaprevir - GLSG DCV/ASV
Gunma University Graduate School of Medicine0 sites100 target enrollmentOctober 1, 2019
Conditionschronic hepatitis C with genotype 1
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- chronic hepatitis C with genotype 1
- Sponsor
- Gunma University Graduate School of Medicine
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients having the history of allergy to Daclatasvir and Asunaprevir 2\. Women with pregnancy, having a possibility of pregnancy and during lactation 3\. Patients taking a medicine described as a contraindication in a package insert. However, these patients can participate the study one month after discontinuation of the drug. 4\. Patients whom the primary doctor thinks inapproprioate for participating the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised control trialHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/06/025575AIIMS Rishikesh
Active, not recruiting
Phase 1
A Phase III Study of the Safety and Efficacy or Entecavir in Pediatric Patients with Chronic HBV-InfectioCHRONIC HEPATITIS B VIRUS,PEDIATRICMedDRA version: 14.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2009-016357-17-BEBristol-Myers Squibb International Corporation180
Completed
Phase 3
Comparative study in childrens with chronic Hepatitis B virus infection who are HBeAg positive.CTRI/2011/09/002001The pharmaceutical company sponsoring this study is BristolMyers Squibb180
Active, not recruiting
Phase 1
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-PositiveCHRONIC HEPATITIS B VIRUS,PEDIATRICMedDRA version: 12.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2009-016357-17-GRBristol-Myers Squibb International Corporation257
Active, not recruiting
Not Applicable
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir versus Adefovir Added to Continuing Lamivudine in Adults with Lamivudine Resistant Chronic Hepatitis B Virus Infection. - NDHepatitis B VirusMedDRA version: 9.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2007-001269-14-ITBRISTOL-M.SQUIBB84